ReachMD

Episodes 16-30 of 124

• 1

  

  RestartResume

  FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
• 2

  

  RestartResume

  FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Ser...
• 12

  

  RestartResume

  Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel D...
• 2

  

  RestartResume

  The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

• • 

    

    Brian P. McDonough, MD, FAAFP

    Peer

  3

  

  RestartResume

  Food-Proof: A USDA Expert's Tips for Avoiding Food Poisoning
• 1

  

  RestartResume

  FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
• 1

  

  RestartResume

  FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
• 1

  

  RestartResume

  FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
• 1

  

  RestartResume

  FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
• 1

  

  RestartResume

  FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
• 1

  

  RestartResume

  FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
• 1

  

  RestartResume

  FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
• 4

  

  RestartResume

  FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
• 4

  

  RestartResume

  Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)
• 0

  

  RestartResume

  Study Examines Effectiveness of Steroid Medication for Sore Throat

• Prev
• 1
• 2
• 3
• 4
• …
• 8
• 9
• Next